Our study solved the limitations of TAM monotherapy, which may lead to recurrence and drug resistance, and also verified that ATRA can regulate ERα-related signaling pathways in ERα-positive ovarian cancer, explaining the mechanism of the combination of the two drugs. This evidence concerns the gene ESR1 and ovarian cancer.